APA (7th ed.) Citation

Sarli, M., Novoa, M. B., Mazzucco, M. N., Signorini, M., Echaide, I. E., Echaide, S. T. d., & Primo, M. E. (2020). A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge. PLOS; National Center for Biotechnology Information.

Chicago Style (17th ed.) Citation

Sarli, Macarena, María Belen Novoa, Matilde N. Mazzucco, Marcelo Signorini, Ignacio Eduardo Echaide, Susana T. de Echaide, and María Evangelina Primo. A Vaccine Using Anaplasma Marginale Subdominant Type IV Secretion System Recombinant Proteins Was Not Protective Against a Virulent Challenge. PLOS; National Center for Biotechnology Information, 2020.

MLA (8th ed.) Citation

Sarli, Macarena, et al. A Vaccine Using Anaplasma Marginale Subdominant Type IV Secretion System Recombinant Proteins Was Not Protective Against a Virulent Challenge. PLOS; National Center for Biotechnology Information, 2020.

IICA/CATIE Citation

Sarli, M., Novoa, M. B., Mazzucco, M. N., Signorini, M., Echaide, I. E., Echaide, S. T. d., ; Primo, M. E. 2020. A vaccine using Anaplasma marginale subdominant type IV secretion system recombinant proteins was not protective against a virulent challenge. PLOS; National Center for Biotechnology Information.